VINBLASTINE

SynDRA canonical compound SYN0002371 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	TUBB
Mechanism of action	Microtubule inhibitor
Indication	Hodgkin's lymphoma \| Kaposi sarcoma \| mycosis \| small lymphocytic lymphoma (SLL) \| testicular carcinoma \| true histiocytic lymphoma (THL)
Disease area	hematologic malignancy \| infectious disease \| oncology

All known targets

vincaleukoblastine
vincaleucoblastin
vincaleucoblastine
vinblastin
vinblastine sulfate
vinblastine sulphate
Vinblastina
[3h]-vinblastine
NSC-47842
Nincaluicolflastine
Rozevin
VLB
Vinblastin
Vinblastinum
Vincaleucoblastin
Vincaleucoblastine
Vincaleukoblastine
Vincoblastine
Vinblastina [DCIT]
VR-8
Vinblastina (TN)
Vinblastine (INN)
Vinblastine [INN:BAN]
Vinblastinum [INN-Latin]
NDC 0002-1452-01
(2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE
(2xi,3beta,4'beta,19xi)-vincaleukoblastine
1H-Indolizino(8,1-cd)carbazole-5-carboxylic acid
Velban
Velbe
CHEMBL159
5V9KLZ54CY
NSC 47842
methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
CCRIS 9002
VINBLASTINE [INN]
HSDB 3263
NCI-C04842